Market Overview:
The global cholesterol drug market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of obesity and other lifestyle diseases, rising geriatric population, and technological advancements in the field of cholesterol drugs. The global cholesterol drug market is segmented on the basis of type, application, and region. On the basis of type, it is divided into statins, PCSK9 inhibitors, selective cholesterol absorption inhibitors (SCAI), and resins. Statins are expected to dominate the market due to their high efficacy and low cost. However, PCSK9 inhibitors are projected to grow at a higher rate during the forecast period owing to their better safety profile as compared statins.
Product Definition:
Cholesterol Drug is a drug that is used to lower cholesterol levels. Cholesterol Drug is important because it helps to prevent heart disease and other health problems.
Statins:
Statin drugs are the most widely used cholesterol-lowering agents in the world. They have been gaining market share at a tremendous rate over the last few years and this trend is expected to continue during the forecast period. Statins are one of those classes of pharmaceuticals that has captured a significant part of modern therapeutics, both in terms of innovation and regulation.
PCSK9 inhibitors:
PCSK9 inhibitors are a new class of cholesterol-lowering drugs that work by targeting and removing the protective coating from “hits” before they can cause damage. The drug is under investigation by numerous research organizations, including the National Institutes of Health (NIH), for its potential to reduce cardiovascular events in people with high cholesterol levels. Currently, there are two PCSK9 inhibitors approved for sale in the U.S.
Application Insights:
The application segment includes the classification of cholesterol drugs by their applications such as cardiology, endocrinology, geriatric medicine and neurology. In 2017, cardiology held the largest market share in terms of revenue owing to rising prevalence of cardiovascular diseases and growing awareness about effective treatment methods. According to a study published in The Lancet in 2016, it was estimated that around 1 billion people had died due to CVDs globally over the past 30 years.
Furthermore, increasing number of clinical trials supporting statin drugs for primary prevention against CVDs along with high demand for these drugs from various patient groups is expected to drive this segment over the forecast period. For instance, according to data published by IMS Health Inc., total sales for Zocor (atorvastatin) capsules increased by 6% from 2015-2016 while sales for Lipitor (atorvastatin) grew at a rate close 2%.
Regional Analysis:
North America dominated the global cholesterol drug market in 2017. This can be attributed to the high prevalence of cardiovascular diseases, rising geriatric population, and availability of effective treatment methods for these conditions. Moreover, increasing government funding for R&D activities pertaining to cholesterol management is also expected to drive growth during the forecast period.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to growing target population base and awareness about early diagnosis coupled with efficient treatment methods offered by international companies such as Johnson & Johnson Services India Pvt Ltd., Cipla Inc., Dr Reddy's Laboratories Limited among others.
Growth Factors:
- Increasing prevalence of lifestyle diseases such as obesity and diabetes, which are major risk factors for heart disease and stroke – both of which are linked with high cholesterol levels.
- Growing awareness among consumers about the importance of maintaining healthy cholesterol levels in order to reduce the risk of heart disease and stroke.
- The increasing number of aging adults – a population that is particularly at risk for developing cardiovascular diseases associated with high cholesterol levels.
- The launch of new, more effective cholesterol-lowering drugs that provide greater efficacy than older medications on the market.
- Increased funding for research into novel treatments for high cholesterol, which could lead to the development of more effective therapies in the future
Scope Of The Report
Report Attributes
Report Details
Report Title
Cholesterol Drug Market Research Report
By Type
Statins, PCSK9 inhibitors, Selective Cholesterol Absorption Inhibitors, Resins
By Application
＜30 Years Old, 30 ~ 50 Years Old, > 50 Years Old
By Companies
Pfizer, Merck, AstraZeneca, Amgen, Sanofi, Sun Pharm, Mylan, TEVA, China National Pharmaceutical Group, PKU Healthcare
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
216
Number of Tables & Figures
152
Customization Available
Yes, the report can be customized as per your need.
Global Cholesterol Drug Market Report Segments:
The global Cholesterol Drug market is segmented on the basis of:
Types
Statins, PCSK9 inhibitors, Selective Cholesterol Absorption Inhibitors, Resins
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
＜30 Years Old, 30 ~ 50 Years Old, > 50 Years Old
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Merck
- AstraZeneca
- Amgen
- Sanofi
- Sun Pharm
- Mylan
- TEVA
- China National Pharmaceutical Group
- PKU Healthcare
Highlights of The Cholesterol Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Statins
- PCSK9 inhibitors
- Selective Cholesterol Absorption Inhibitors
- Resins
- By Application:
- ＜30 Years Old
- 30 ~ 50 Years Old
- > 50 Years Old
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cholesterol Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A cholesterol drug is a medication that lowers blood cholesterol levels.
Some of the major companies in the cholesterol drug market are Pfizer, Merck, AstraZeneca, Amgen, Sanofi, Sun Pharm, Mylan, TEVA, China National Pharmaceutical Group, PKU Healthcare.
The cholesterol drug market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cholesterol Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cholesterol Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cholesterol Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cholesterol Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cholesterol Drug Market Size & Forecast, 2020-2028
4.5.1 Cholesterol Drug Market Size and Y-o-Y Growth
4.5.2 Cholesterol Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Statins
5.2.2 PCSK9 inhibitors
5.2.3 Selective Cholesterol Absorption Inhibitors
5.2.4 Resins
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 ＜30 Years Old
6.2.2 30 ~ 50 Years Old
6.2.3 > 50 Years Old
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cholesterol Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cholesterol Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Statins
9.6.2 PCSK9 inhibitors
9.6.3 Selective Cholesterol Absorption Inhibitors
9.6.4 Resins
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 ＜30 Years Old
9.10.2 30 ~ 50 Years Old
9.10.3 > 50 Years Old
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Statins
10.6.2 PCSK9 inhibitors
10.6.3 Selective Cholesterol Absorption Inhibitors
10.6.4 Resins
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 ＜30 Years Old
10.10.2 30 ~ 50 Years Old
10.10.3 > 50 Years Old
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Statins
11.6.2 PCSK9 inhibitors
11.6.3 Selective Cholesterol Absorption Inhibitors
11.6.4 Resins
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 ＜30 Years Old
11.10.2 30 ~ 50 Years Old
11.10.3 > 50 Years Old
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Statins
12.6.2 PCSK9 inhibitors
12.6.3 Selective Cholesterol Absorption Inhibitors
12.6.4 Resins
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 ＜30 Years Old
12.10.2 30 ~ 50 Years Old
12.10.3 > 50 Years Old
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Statins
13.6.2 PCSK9 inhibitors
13.6.3 Selective Cholesterol Absorption Inhibitors
13.6.4 Resins
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 ＜30 Years Old
13.10.2 30 ~ 50 Years Old
13.10.3 > 50 Years Old
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cholesterol Drug Market: Competitive Dashboard
14.2 Global Cholesterol Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Merck
14.3.3 AstraZeneca
14.3.4 Amgen
14.3.5 Sanofi
14.3.6 Sun Pharm
14.3.7 Mylan
14.3.8 TEVA
14.3.9 China National Pharmaceutical Group
14.3.10 PKU Healthcare
